Acute Care of COPD: Gaps in our knowledge. Robert A. Wise, M.D. May 20, 2010
|
|
- Moris Dwain Sharp
- 8 years ago
- Views:
Transcription
1 Acute Care of COPD: Gaps in our knowledge Robert A. Wise, M.D. May 20, 2010
2 Outline of talk Importance of COPD exacerbations Current treatments Areas for improvement Significant knowledge gaps Strategies for improving care
3 Importance of COPD exacerbations
4 Outcome of Exacerbations Room for In outpatients Improvement Treatment failure rate 13%-33% In ER patients In hospitalized patients In ICU patients Relapse (repeat ER visit) Hospital mortality Hospital mortality 22%-32% 5%-10% 20%-24% Seneff et al. JAMA. 1995; 274: ; Murata et al. Ann Emerg Med. 1991;20: ; Adams et al. Chest. 2000;117:
5 Exacerbations Affect Quality of Life SGRQ Score * Total * * * 48 SymptomsActivities Impacts Activities 0-2 Exacerbations 3-8 Exacerbations * P<0.05 versus lower exacerbation rate Seemungal TA, et al. Am J Respir Crit Care Med. 2000;161:
6 Baseline Rate of Change in SGRQ (control group) and Exacerbation Frequency During the UPLIFT Trial Rate of change in SGRQ total score (units/yr) >0 to 1 >1 to 2 >2 Exacerbation Rate (per patient-year) SGRQ, St George s Respiratory Questionnaire
7 High Mortality Following Emergency Department Visit for COPD Exacerbation Percent Mortality 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 5% 9% 11% 16% 23% 32% 39% 30 Days 60 Days 90 Days 180 Days 1 Year 2 Years 3 Years Time Following Visit Kim S, et al. COPD. 2006;3:
8 Effects of Repeated Exacerbations on Survival 1.0 Prospective study Cohort of 304 males Exacerbations requiring hospital treatment during the year Follow-up over 5 years Probability of surviving No exacerbation p< exacerbations p= exacerbations Soler-Cataluña JJ et al. Thorax 2005;64: Time (months)
9 2010 projected Health Care Costs for COPD Long-term Care, $3.7 Home Health Care, $1.3 Prescriptions, $5.8 Hospital Care, $13.2. Cost in Billions Total = $29.5 Physican Fees, $5.5 Hospital Care Physican Fees Prescriptions Home Health Care Long-term Care
10 Recurrence of Exacerbations 27% of first exacerbations associated with second exacerbation in 8 weeks 34% of 1,221 hospitalized patients in UK readmitted within 3 months (range 5-65%) C M Roberts et al.thorax 2002;57: Hurst et al. Am J Respir Crit Care Med 2009; 179:369
11 Effects of Repeated Exacerbations on Recovery of QoL 60 N=133 6-month prospective study SGRQ total score N=299 N=133 N=280 N=116 N=233 N=115 N=221 After one exacerbation treated with antibiotics Followed for 26 weeks. 31% had recurrent exacerbation N =Patients remaining in the study at that time point With a further exacerbation 30 Presentation 4 weeks 12 weeks 26 weeks No new exacerbation Spencer S. et al. Thorax 2003;58:589
12 Recurrent admissions after hospital discharge the critical issue for COPD in % of patients account for 70% of costs Medicare reimbursement schedule makes hospitals interested High mortality in frequent exacerbators Wide range of readmissions at hospitals (5-65%) Event rate high enough to study easily Outcome measure easy to count We can probably do something about it
13 Triple therapy Fewer hospitalizations % Pts with 1 or more exacerbation(s) Tiotropium (n=156) Tiotropium + Salmeterol (n=148) Tiotropium + Salmeterol + Fluticasone (n=145) 62.8 % 64.8% 60.0% Total Exacerbations Exacerbations with Hosp * Aaron et. al. Ann Int Med. 2007
14 Checklist for Acute Coronary Syndrome Discharge ASA ACE / ARB Beta-blocker Statin Rehabilitation / Exercise prescription Smoking cessation treatment / adjuncts Hypertension treated
15 Checklist for AE-COPD Discharge Has he got a way to get home?
16 Checklist for AE-COPD Discharge ICS / LABA LAMA Inhaler instruction with actual devices Oxygen instruction Steroid taper instruction and monitoring Rehabilitation / Exercise prescription Self-management care plan Follow-up care plan Drug affordability
17
18 Need for economic analyses?
19 Cost-Utility Analyses - TORCH Salmeterol-Fluticasone $33,865 / QALY Salmeterol alone $20,792 / QALY Fluticasone null Salmeterol-Fluticasone $52,046 / QALY Salmeterol alone $56,519 / QALY Salmeterol-Fluticasone $43,600 / QALY Salmeterol alone $197,000 / QALY Earnshaw et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med Jan;103(1): Oba Y.et al. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care. 2009;15: Briggs A et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010;35:532-9
20 Etiology of Exacerbations of COPD Non-infectious e.g., air pollution. climate change, noncompliance,etc. Bacteria Virus Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11 Bacteria and virus
21 Immunization Influenza vaccination Pneumococcal vaccination
22 Pneumococcal Vaccine Dec-March Relative Risk of Death P = Pneumococcal vaccine I = Influenza vaccine n = 177, * 0.53 * 1 * 0 I+/P- I+/P+ I-/P- I-/P+ Vaccination status Schembri S. et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64: Adjusted for age, gender, Co-morbidities
23 Pneumococcal Vaccine Apr-Nov Relative Risk of Death P = Pneumococcal vaccine I = Influenza vaccine n = 177, * I+/P- I+/P+ I-/P- I-/P+ Vaccination status Schembri S. et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64: Adjusted for age, gender, Co-morbidities
24 Key questions Is it harmful to give pneumococcal vaccine? Is it beneficial to give influenza vaccine for hospitalized COPD patients on steroids?
25 Helium-Oxygen Mixtures Improves exercise tolerance and dynamic hyperinflation in COPD Does not improve bronchodilator response as carrier for nebulizer Question: Can Heliox by inhalation or by NIPPV prevent intubation or improve outcomes compared with NIPPV alone? Rodrigo G, Pollack C, Rodrigo C, Rowe B. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(2):CD
26 Heliox and PPV reduces work of breathing during COPD exacerbations Jaber S, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:
27 Heliox and PPV decrease PaCO2 during COPD exacerbations Jaber S, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:
28 Self Management / Case Management Can t hurt, can it?
29 Self Management Cochrane Systematic Review because of heterogeneity in interventions, study populations, follow-up time, and outcome measures, data are still insufficient to formulate clear recommendations regarding the form and contents of self-management education programmes in COPD. There is an evident need for more large RCTs with a long-term follow-up, before more conclusions can be drawn. Effing et al. Self-Management education for patients with COPD. Cochrane Review :CD002990
30 Care Management in COPD N = 743 pts Usual Care vs Disease Management 1.5 hr education Action plan for self treatment Monthly f/u calls from case manager Results: All cause hospitalizations decreased 28% Rice KL, Disease Management Program for Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Am J Respir Crit Care Med Jan 21. Epub.
31 Mucolytics Meta-analysis of 28 trials with 7,042 pts. 21% reduction in exacerbation rate 44% reduction in days of disability 1.93 OR of remaining exacerbation free Possibly increased benefit in patients NOT on ICS Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Reviews 2010, CD
32 Carbocysteine PEACE Trial Carbocysteine exac/yr Placebo 1.35 exac/yr P = No effect for 3 months No interaction with ICS, smoking status Zheng JP.. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371::2013-8
33 Corticosteroids for COPD exacerbation in hospital Hospital days Decreased from 9.7 to 8.5 in steroid group Niewoehner DE, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. VA Study Group. N Engl J Med. 1999;340:1941-7
34 Oral steroids after ER visit for COPD Aaron SD, et al.. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:
35 Steroid Resistance in COPD Induced by oxidative / nitrosative stress on HDAC2 Reduced by theophylline, anti-oxidant treatments Can adjuvants be used to augment corticosteroid efficacy? Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med ;200:689-95
36 Etiology of Exacerbations of COPD Non-infectious e.g., air pollution. climate change, noncompliance,etc. Bacteria Virus Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11 Bacteria and virus
37 Inhalation during swallowing in COPD 14% 12% 10% 8% 6% 4% 2% 0% O.R. = 4.4, p < O.R. = 1.23, p = 0.44 Cookie Pudding COPD Control Gross RD et al. The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:559-65
38 Can we prevent exacerbations with aspiration precautions, swallowing training, or dietary modification?
39 Etiology of Exacerbations of COPD Non-infectious e.g., air pollution. climate change, noncompliance,etc. Bacteria Virus Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11 Bacteria and virus
40 Antibiotics Zpak is a simple prescription to write because it comes in a selfexplanatory packet. --- Indiana School of Optometry
41 Erythromcycin decreases frequency, severity and time to first exacerbation N = 109 pts Erythromycin 250mg bid 36% reduction in exacerbations Seemungal TA, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:
42 Clinical trial of doxycycline in COPD flares treated with corticosteroids No difference in 30 day outcomes Improved efficacy at day 10 Daniels JM, et. al.. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:150-7
43 Impaired macrophage clearance of bacteria in COPD reversed with sulforaphane % Inoculated CFUs Vehicle PA * Sulforaphane P1 250 P2 200 P3 P4 150 P5 100 P6 P7 50 P8 P9 0 % Inoculated CFUs Vehicle NTHI * Sulforaphane P6 P7 P8 P9 P10 P11 P12 P13 P14 Courtesy of C. Harvey, S. Biswal
44 Key Messages Recurrent hospital admissions are a major lever point for improving COPD care The future probably lies with real-world studies of combined therapies Both administrative and pharmacological strategies need to be explored conjointly
45 Thank you!
Prevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More informationPLAN OF ACTION FOR. Physician Name Signature License Date
PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes
More informationIrish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy
31 st Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy 1 Introduction Chronic obstructive pulmonary disease (COPD) is an important disease for patients, the health
More informationBronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
More informationManagement of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
More informationRES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP
RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families
More informationSevere asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital
Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,
More information3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients
Faculty Disclosures COPD Disease Management Tackling the Transition Dr. Cappelluti has no actual or potential conflicts of interest associated with this presentation. Jane Reardon has no actual or potential
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More informationPathway for Diagnosing COPD
Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational
More informationJ of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575
EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma
More informationPulmonary rehabilitation
29 Pulmonary rehabilitation Background i Key points There is a sound evidence base showing the effects of pulmonary rehabilitation on chronic obstructive pulmonary disease symptoms and health-related quality
More informationPCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]
PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationWaterloo Wellington Rehabilitative Care System Integrated Care Pathway for COPD Stream of Care (short version)
Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for COPD Stream of Care (short version) Care Setting ACUTE Activity Confirmation of COPD diagnoses: If time and the patient s condition
More informationAchieving Quality and Value in Chronic Care Management
The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of
More informationValue of Homecare: COPD and Long-Term Oxygen Therapy. A White Paper
Value of Homecare: COPD and Long-Term Oxygen Therapy A White Paper Chronic Obstructive Pulmonary Disease (COPD) is the 4 th leading cause of death in the world and afflicts over 14 million Americans. The
More informationCo-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans op longkanker dan rokers
Academisch centrum huisartsgeneeskunde Pneumologie Juni 2012 Prof W Janssens Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans
More informationTopic: New Treatment = Better Outcome?
Session on COPD: Novel Concepts and Promising New Drugs Topic: New Treatment = Better Outcome? Through a CME Grant sponsored by New Treatment = Better Outcome? Tim S. Trinidad, MD Disclosure Present: COPD
More informationCost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary
More informationCOPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationHome Telehealth for Patients With Chronic Obstructive Pulmonary Disease (COPD): An Evidence-Based Analysis
Home Telehealth for Patients With Chronic Obstructive Pulmonary Disease (COPD): An Evidence-Based Analysis J Franek March 2012 Ontario Health Technology Assessment Series; Vol. 12: No. 11, pp. 1 58, March
More informationHospital-at-Home Programs for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): An Evidence-Based Analysis
Hospital-at-Home Programs for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): An Evidence-Based Analysis BR McCurdy March 2012 Ontario Health Technology Assessment Series;
More informationPulmonary Rehabilitation in Newark and Sherwood
Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published
More informationHospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care
Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care Charley P. Starnes, RRT, RCP Clinical Respiratory Specialist- COPD Education Important Milestones July 2011-
More informationExploring the Chronic Obstructive Pulmonary Disease (COPD) Clinical Pathway. Health Quality Ontario s integrated episode of care for COPD
Exploring the Chronic Obstructive Pulmonary Disease (COPD) Clinical Pathway Health Quality Ontario s integrated episode of care for COPD Dr. Charlie Chan Health Quality Ontario Expert Panel Co-Chair May/June
More informationChronic Obstructive Pulmonary Disease (COPD) Admission Order Set
Patient Name: PHN: Page 1/1 Admit to Dr: Notified Consult: Dr: Family Dr: Precautions: Contact Droplet Enhanced Droplet Airborne - Reason: _ Code Status: Full Resuscitation or Consults: Reason: Dietician
More informationCOPD - Education for Patients and Carers Integrated Care Pathway
Patient NHS COPD - Education for Patients and Carers Integrated Care Pathway Date ICP completed:. Is the patient following another Integrated Care Pathway[s].. / If yes, record which other Integrated Care
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationThe Cost-Effectiveness of Homecare
The Cost-Effectiveness of Homecare Homecare Reduces Costs by 37 Percent for Heart Failure Patients The May 2004 Journal of the American Geriatrics Society reports a study conducted at six Philadelphia
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationPulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Development of disability in COPD The decline in airway function may initially go unnoticed as people adapt their lives to avoid
More informationChronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways
More informationImprovement in Dyspnea Implementing Pulmonary Rehabilitation in the Home
Improvement in Dyspnea Implementing Pulmonary Rehabilitation in the Home Mary Cesarz MS, PT Lisa Gorski MS, APRN, BC, FAAN Wheaton Franciscan Home Health & Hospice Milwaukee, WI Objectives To identify
More informationService delivery interventions
Service delivery interventions S A S H A S H E P P E R D D E P A R T M E N T O F P U B L I C H E A L T H, U N I V E R S I T Y O F O X F O R D CO- C O O R D I N A T I N G E D I T O R C O C H R A N E E P
More informationCLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease
CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationWandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15
Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15 April 2015 Dr Kieron Earney & Kate Symons Acknowledgements Dr Sarah Deedat Public Health Lead for Long Term Conditions 1 1.
More informationLongitudinal Modeling of Lung Function in Respiratory Drug Development
Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief
More informationMean Duration (days) ± SD b. n = 587 n = 587
Online Table 1. Length of stay in matched cohorts of patients with VA and patients without VA a MS-DRG opulation (Code) ECMO or tracheostomy with mechanical ventilation 96 hours or principal diagnosis
More informationBest Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)
Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Reliant Medical Group Case Study Organization Profile Reliant Medical Group (formerly Fallon Clinic) was founded in
More informationNational Learning Objectives for COPD Educators
National Learning Objectives for COPD Educators National Learning Objectives for COPD Educators The COPD Educator will be able to achieve the following objectives. Performance objectives, denoted by the
More information11/2/2015 Domain: Care Coordination / Patient Safety
11/2/2015 Domain: Care Coordination / Patient Safety 2014 CT Commercial Medicaid Compared to 2012 all LOB Medicaid Quality Compass Benchmarks 2 3 4 5 6 7 8 9 10 Documentation of Current Medications in
More information2013 ACO Quality Measures
ACO 1-7 Patient Satisfaction Survey Consumer Assessment of HealthCare Providers Survey (CAHPS) 1. Getting Timely Care, Appointments, Information 2. How well Your Providers Communicate 3. Patient Rating
More informationRehabilitation and Lung Cancer Resection. Roberto Benzo MD MS Mindful Breathing Laboratory Division of Pulmonary & CCM Mayo Clinic
Rehabilitation and Lung Cancer Resection Roberto Benzo MD MS Mindful Breathing Laboratory Division of Pulmonary & CCM Mayo Clinic Disclosure Funded by the National Cancer Institute NIH for Preoperative
More informationMedication and Devices for Chronic Obstructive Pulmonary Disease (COPD)
Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators
More informationCURRICULUM VITAE KIRK GEORGE VOELKER, M.D.
PERSONAL INFORMATION DATE OF BIRTH December 29, 1961 PLACE OF BIRTH OFFICE ADDRESS E-MAIL Buffalo, NY. 1537 State St. 34236 (941) 330-1696 Dr.Voelker@comcast.net ACADEMIC RECORD UNDERGRADUATE MEDICAL SCHOOL
More informationHow to use FENO-guided asthma control in routine clinical practice
How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region November 2015 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationPosition Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis
BACKGROUND Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic and fatal disease characterised by
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationExploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
More information5. Treatment of Asthma in Children
Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationHow can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
More informationCOPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationHow To Write A Systematic Review
Formulating the Review Question & Writing a Protocol Madhukar Pai, MD, PhD Associate Professor Department of Epidemiology & Biostatistics McGill University, Montreal, Canada Email: madhukar.pai@mcgill.ca
More informationIN-HOME QUALITY IMPROVEMENT. BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK
IN-HOME QUALITY IMPROVEMENT BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK Best Practice Intervention Packages were designed for use by any In-Home Provider Agency
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationRED, BOOST, and You: Improving the Discharge Transition of Care
RED, BOOST, and You: Improving the Discharge Transition of Care Jeffrey L. Greenwald, MD, SFHM Massachusetts General Hospital - Clinician Educator Service Co-Investigator Project RED & Project BOOST The
More informationCOPD Patient 30-Day Hospital Readmission Reduction Program
White Paper COPD Patient 30-Day Hospital Readmission Reduction Program Brian Tiep, MD; Brian Carlin, MD; Trina Limberg, RRT; Robert McCoy, RRT Abstract: The U.S. Patient Protection and Affordable Care
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationPulmonary Rehabilitation: more than just an exercise prescription
Pulmonary Rehabilitation: more than just an exercise prescription Robert Stalbow, RRT, RCP Pulmonary Rehabilitation Therapist Oregon Heart & Vascular Institute Objectives To describe the role of pulmonary
More informationBefore prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.
Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler
More informationOriginal Article COPD and Hospital Stay Pak Armed Forces Med J 2014; 64 (1): 46-50. Ahmed Raza, Mahmood Iqbal Malik*, Yousaf Jamal**
Original Article COPD and Hospital Stay Pak Armed Forces Med J 2014; 64 (1): 46-50 COMPARISON OF NIPPV WITH STANDARD TREATMENT IN PATIENTS WITH ACUTE EXACERBATIONS OF COPD IN TERMS OF IMPROVEMENT IN ABGS
More informationClinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms
Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,
More informationContents. Effective Health Care Research Report Number 16
The DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) network is part of AHRQ's Effective Health Care Program. It is a collaborative network of research centers that support the rapid
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationCURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP
CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP Business address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, Fl Phone: 941.951.3920 Fax: 941.951.3922 Prior business
More informationClinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms
Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,
More informationMedicare Shared Savings Program Quality Measure Benchmarks for the 2015 Reporting Year
Medicare Shared Savings Program Quality Measure Benchmarks for the 2015 Reporting Year Release Notes/Summary of Changes (February 2015): Issued correction of 2015 benchmarks for ACO-9 and ACO-10 quality
More informationMedicare 2015 QI Program Evaluation
Color Code: Red does not meet 5 star threshold, or target. Green meets or exceeds 5 star threshold/target. Improving or Maintaining Physical Health (HOS) Improving or Maintaining Mental Health (HOS) Diabetes
More informationReducing COPD Readmissions and Implications for Pulmonary Rehab. Janie Knipper, APN, MA, AE-C, FAACVPR jane-knipper@uiowa.edu
Reducing COPD Readmissions and Implications for Pulmonary Rehab Janie Knipper, APN, MA, AE-C, FAACVPR jane-knipper@uiowa.edu Statement of Disclosure I have no disclosures. The opinions expressed are my
More informationAECOPD: Management and Prevention
AECOPD: Management and Prevention Neil MacIntyre MD Duke University Medical Center Durham NC AECOPD: Management and Prevention AECOPD: Definitions and impact Acute management of AECOPD Preventing AECOPD.
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationObjectives. Asthma Management
Objectives Asthma Management BREATHE Conference Allergy and Asthma Specialists PC Christine Malloy MD March 22, 2013 Review the role of inflammation in asthma Discuss the components of the EPR-3 management
More informationKEYWORDS Chronic obstructive pulmonary disease Exacerbation Respiratory viruses Bacteria
COPD Exacerbations Causes, Prevention, and Treatment Alex J. Mackay, MBBS, BSc (Hons), MRCP*, John R. Hurst, PhD, FRCP KEYWORDS Chronic obstructive pulmonary disease Exacerbation Respiratory viruses Bacteria
More informationDepartment of Surgery
What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.
More informationCOPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and
More information2010 QARR QUICK REFERENCE GUIDE Adults
2010 QARR QUICK REFERENCE GUIDE Adults ADULT MEASURES (19 through 64 years) GUIDELINE HEDIS COMPLIANT CPT/ICD9 CODES DOCUMENTATION TIPS Well Care Access to Ambulatory Care Ensure a preventive or other
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationSouthwark Clinical Commissioning Group Lambeth Clinical Commissioning Group
Getting the Vision Right: A multi-disciplinary approach to providing integrated care for respiratory patients Dr Noel Baxter, GP NHS Southwark CCG Dr Irem Patel, Integrated Consultant Respiratory Physician
More informationChronic Critical Illness: Can it be prevented? Carmen C Polito, MD Pulmonary & Critical Care Medicine Emory University Atlanta, GA cpolito@emory.
Chronic Critical Illness: Can it be prevented? Carmen C Polito, MD Pulmonary & Critical Care Medicine Emory University Atlanta, GA cpolito@emory.edu Data free zone Disclosures A (Very) Old Case 65 year-old
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationUnderstanding COPD. Carolinas Healthcare System
Understanding COPD Carolinas Healthcare System 2013 This self-directed learning module contains information about the pathophysiology, diagnosis, and treatment of COPD. Target Audience: All RNs and LPNs
More informationCOPD with Respiratory Failure Case Study #21. Molly McDonough
COPD with Respiratory Failure Case Study #21 Molly McDonough Patient: Mr. Hayato 65 year old male Brought to ER with severe SOB Past History of emphysema Longstanding chronic obstruction pulmonary disease
More informationPrevention of Acute Exacerbations of COPD American College of Chest Physicians and Canadian Thoracic Society Guideline
[ Evidence-Based Medicine ] Prevention of Acute Exacerbations of COPD American College of Chest Physicians and Canadian Thoracic Society Guideline Gerard J. Criner, MD, FCCP ; Jean Bourbeau, MD, FCCP ;
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationWeaning the Unweanable
Weaning the Unweanable Gerald W. Staton, Jr, MD Professor of Medicine Pulmonary & Critical Care Medicine Emory University School of Medicine Atlanta, GA gerald.staton@emory.edu Disclosures Pulmonary Program
More informationStress is linked to exaggerated cardiovascular reactivity. 1) Stress 2) Hostility 3) Social Support. Evidence of association between these
Psychosocial Factors & CHD Health Psychology Psychosocial Factors 1) Stress 2) Hostility 3) Social Support Evidence of association between these psychosocial factors and CHD Physiological Mechanisms Stress
More informationPFF DISEASE EDUCATION WEBINAR SERIES. Welcome!
PFF DISEASE EDUCATION WEBINAR SERIES Welcome! ASK A DOC Q+A WITH PFF MEDICAL TEAM Harold Collard, MD PFF Senior Medical Advisor, Research Advisory Forum Gregory Cosgrove, MD PFF Chief Medical Officer David
More informationPerformance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis
Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Methodology: 8 respondents The measures are incorporated into one of four sections: Highly
More informationBreathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease
Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease By John W. Walsh, Co-Founder and President of the COPD Foundation Breathing Easier In
More informationSUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES
Summary Table of Measures, Product Lines and Changes 1 SUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES General Guidelines for Data Collection and Reporting Guidelines for Calculations and Sampling
More information